DreamFold leverages generative AI algorithms in the design of protein therapeutics to address significant biological challenges related to human disease.
DreamFold is building a next-generation protein therapeutics platform that combines advanced AI-driven protein design, generative modelling, and high-throughput screening to rapidly create new classes of protein drugs. By systematically engineering proteins to modulate disease targets once considered “undruggable”, DreamFold aims to transform outcomes for patients who currently lack safe, effective treatments.
DreamFold was founded at MILA, a globally renowned AI research institute, and the team regularly releases state of the art protein design ML models.
